PHASE FOUR REVIEW

(NOTE: This only contains additions and changes from the phase 2 response.)

Pesticide: Ametryn
Transmitted to HED on: 9-13-90
Chemical#/Case#: 80801 / 2010
Tox. Chem #: 431
Sponsor: Ciba Geigy
CRM: Tom Luminello
Phone#: 557-2558
Branch: TOX-I
Reviewer: John E. Whalan
Completed: 09/25/90
Concurrence:

Are there any changes from the reviews in phase 2? XX

(See below)

Response, by Guideline

Guideline #: 81-1

MRID 40995814 Study #5567-88
Acute oral/rat
Discussion/Recommendation:

No change.
NOTE: The purity of the test article which was missing in the original report was reported in the summary.

Guideline #: 81-2

MRID 40995815 Study #5567-88
Acute dermal/rabbit
Discussion/Recommendation:

No change.
NOTE: The purity of the test article which was missing in the original report was reported in the summary.

Guideline #: 81-3

MRID 40995816 Study #5571-88
Acute inhalation/rat
Discussion/Recommendation:

No change.
NOTE: The purity of the test article which was missing in the original report was reported in the summary.
Guideline #: 81-4

MRID 40995817 Study #5568-88
Discussion/Recommendation:

No change.
NOTE: The purity of the test article which was missing in the original report was reported in the summary.

Guideline #: 81-5

MRID 40995818 Study #5569-88
Discussion/Recommendation:

No change.
NOTE: The purity of the test article which was missing in the original report was reported in the summary.

Guideline #: 81-6

MRID 40995819 Study #5570-88
Discussion/Recommendation:

No change.
NOTE: The purity of the test article which was missing in the original report was reported in the summary.

Guideline #: 82-2

MRID 41067902 Study #882215
Discussion/Recommendation:

Although a study has been performed, it has yet to be submitted for review. Study deficiencies recognized by the Registrant include the absence of urinalysis and lung histopathology, and the dosing of less than 10% of the body surface area. Based on a preliminary assessment of the summary, the study is acceptable for review.

Guideline #: 83-1a

MRID Study #
Discussion/Recommendation:

See Guideline 83-5.
Guideline #: 83-1b

MRID 40349902 Study #842118
Discussion/Recommendation:

No change.

Guideline #: 83-2a

MRID Study #____
Discussion/Recommendation:

See Guideline 83-5.

Guideline #: 83-2b

MRID 40349904 Study #483-128
Discussion/Recommendation:

No Change.
NOTE: The Registrant submitted a summary for a 28-day range-finding study which was used to select doses for the chronic study. The summary only served to demonstrate the failure to select adequate doses.

Guideline #: 83-3a

MRID 153215 Study #852054
Discussion/Recommendation:

The summary resolved questions about test article purity, stability, and homogeneity. Based on a preliminary assessment of the summary, the study is acceptable for review.

Guideline #: 83-3b

MRID 153214 Study #842107
Discussion/Recommendation:

The summary resolved questions about test article purity, stability, and homogeneity. Based on a preliminary assessment of the summary, the study is acceptable for review.
Guideline #: 83-4

MRID 92002-026 Study #852048
Discussion/Recommendation:

The summary resolved questions about test article purity, stability, homogeneity, and dose concentration. Based on a preliminary assessment of the summary, the study is acceptable for review.

Guideline #: 83-5

MRID 40349906 Study #842119
Discussion/Recommendation:

No change.

Guideline #: 84-2a

MRID 40995820 Study #840802
Discussion/Recommendation:

No change.

Guideline #: 84-2b

MRID 41067903 Study #881548
Discussion/Recommendation:

No change.

Guideline #: 84-4

MRID 41067904 Study #881549
Discussion/Recommendation:

No change.

Guideline #: 85-1

MRID 41463301 Study #RPT0022
Discussion/Recommendation:

This study has not been submitted to HED for review, and it is not listed in the bibliography (dated April 7, 1989). A screen could not be performed because only a brief study summary was provided. Based on a preliminary assessment of the summary, the study is acceptable for review.